Form 13-F position report

RIGEL PHARMACEUTICALS INC

Reported by ARMISTICE CAPITAL LLC

RIGL CUSIP 766559702 Manager CIK 0001601086

Reported 1,536,000 shares, down 136,000 (8.1%) from the prior quarter.

Reported value 13.1%; share count -8.1% vs. the prior quarter.

Reduced
% of reported 13F value 0.91% This manager · Q3 2026
Shares 1,536,000 Quarter-end amount reported
Reported value $73,958,400 Fair value at quarter end
Consecutive quarters held 17 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-09-30 4074000
2022-12-31 25434000
2023-03-31 22471680
2023-06-30 22059000
2023-09-30 18506880
2023-12-31 24795000
2024-03-31 22732800
2024-06-30 0
2024-06-30 13349280
2024-09-30 24852480
2024-12-31 19376640
2025-03-31 27272840
2025-06-30 29968000
2025-09-30 20510920
2025-12-31 35805880
2026-03-31 34611200
2026-06-30 65408640
2026-09-30 73958400

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for RIGEL PHARMACEUTICALS INC held by ARMISTICE CAPITAL LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 1,536,000 -136,000 (-8.1%) 0.91% $73,958,400 2026-11-16
Q2 2026 Added 1,672,000 +392,000 (30.6%) 0.8% $65,408,640 2026-08-14
Q1 2026 Added 1,280,000 +444,000 (53.1%) 0.62% $34,611,200 2026-05-15
Q4 2025 Added 836,000 +112,000 (15.5%) 0.43% $35,805,880 2026-02-17
Q3 2025 Reduced 724,000 -876,000 (-54.8%) 0.3% $20,510,920 2025-11-17
Q2 2025 Added 1,600,000 +84,000 (5.5%) 0.52% $29,968,000 2025-08-14
Q1 2025 Added 1,516,000 +364,000 (31.6%) 0.41% $27,272,840 2025-05-15
Q4 2024 Reduced 1,152,000 -384,000 (-25.0%) 0.26% $19,376,640 2025-02-14
Q3 2024 Reduced 1,536,000 -88,000 (-5.4%) 0.4% $24,852,480 2024-11-14
Q2 2024 New 1,624,000 +1,624,000 (0.0%) 0.17% $13,349,280 2024-08-14
Q2 2024 Reduced 0 -15,360,000 (-100.0%) 0 $0 2024-08-14
Q1 2024 Reduced 15,360,000 -1,740,000 (-10.2%) 0.3% $22,732,800 2024-05-15
Q4 2023 Reduced 17,100,000 -36,000 (-0.2%) 0.34% $24,795,000 2024-02-13
Q3 2023 Added 17,136,000 +36,000 (0.2%) 0.28% $18,506,880 2023-11-14
Q2 2023 Added 17,100,000 +76,000 (0.4%) 0.32% $22,059,000 2023-08-14
Q1 2023 Added 17,024,000 +68,000 (0.4%) 0.32% $22,471,680 2023-05-15
Q4 2022 Added 16,956,000 +13,503,126 (391.1%) 0.44% $25,434,000 2023-02-14
Q3 2022 New 3,452,874 +3,452,874 (0.0%) 0.07% $4,074,000 2022-11-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

187 managers reported RIGEL PHARMACEUTICALS INC for Q3 2026.

Managers reporting RIGEL PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 2,065,776 +125,958 < 0.01% $99,467,127 9 qtrs
Soleus Capital Management L P Unchanged 1,843,504 0 3.16% $88,764,718 10 qtrs
ARMISTICE CAPITAL LLC This report Reduced 1,536,000 -136,000 0.91% $73,958,400 10 qtrs
MORGAN STANLEY Added 1,256,819 +1,070,770 < 0.01% $60,515,834 10 qtrs
AMERICAN CENTURY COMPANIES INC Added 1,043,966 +302,248 0.02% $50,266,963 6 qtrs
STATE STREET CORPORATION Reduced 879,862 -160,132 < 0.01% $42,365,355 10 qtrs
LSV ASSET MANAGEMENT Added 787,408 +65,742 0.07% $37,914,000 6 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Reduced 782,703 -2,404 < 0.01% $37,687,149 3 qtrs
Assenagon Asset Management S A New 535,685 +535,685 0.02% $25,793,233 1 qtr
GEODE CAPITAL MANAGEMENT LLC Reduced 482,976 -199 < 0.01% $23,260,958 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,536,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.